241 related articles for article (PubMed ID: 7684788)
1. Microbiology of cystic fibrosis lung infections: themes and issues.
Govan JR; Nelson JW
J R Soc Med; 1993; 86 Suppl 20(Suppl 20):11-8. PubMed ID: 7684788
[No Abstract] [Full Text] [Related]
2. Microbiology of lung infection in cystic fibrosis.
Govan JR; Nelson JW
Br Med Bull; 1992 Oct; 48(4):912-30. PubMed ID: 1281036
[TBL] [Abstract][Full Text] [Related]
3. Pseudomonas aeruginosa and Burkholderia cepacia cannot be detected by PCR in the breath condensate of patients with cystic fibrosis.
Vogelberg C; Hirsch T; Rösen-Wolff A; Kerkmann ML; Leupold W
Pediatr Pulmonol; 2003 Oct; 36(4):348-52. PubMed ID: 12950050
[TBL] [Abstract][Full Text] [Related]
4. Sequencing of the Pseudomonas aeruginosa and Burkholderia cepacia genomes and their applications in relation to cystic fibrosis.
Miller DA; Mahenthiralingam E
J R Soc Med; 2003; 96 Suppl 43(Suppl 43):57-65. PubMed ID: 12906327
[No Abstract] [Full Text] [Related]
5. [Current microbiological data on lower respiratory tract infection in cystic fibrosis. Part I: Isolated microorganisms and their clinical significance].
Coman G; Petraru E; Dahorea C; Anton DT
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):580-7. PubMed ID: 23077957
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of minocycline against respiratory pathogens from patients with cystic fibrosis.
Kurlandsky LE; Fader RC
Pediatr Pulmonol; 2000 Mar; 29(3):210-2. PubMed ID: 10686042
[TBL] [Abstract][Full Text] [Related]
7. Pseudomonas aeruginosa aggregates in cystic fibrosis sputum produce exopolysaccharides that likely impede current therapies.
Jennings LK; Dreifus JE; Reichhardt C; Storek KM; Secor PR; Wozniak DJ; Hisert KB; Parsek MR
Cell Rep; 2021 Feb; 34(8):108782. PubMed ID: 33626358
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic therapy in cystic fibrosis. Evaluation of efficacy.
Levy J
Chest; 1988 Aug; 94(2 Suppl):150S-156S. PubMed ID: 3135160
[TBL] [Abstract][Full Text] [Related]
9. [Isolation frequency of Burkholderia cepacia from cystic fibrosis patients].
Ocak F; Gözalan A; Ozçelik U; Anadol D; Kiper N; Aktepe OC; Göçmen A; Esen B
Mikrobiyol Bul; 2002 Jan; 36(1):1-10. PubMed ID: 12476760
[TBL] [Abstract][Full Text] [Related]
10. Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections.
Waters VJ; Kidd TJ; Canton R; Ekkelenkamp MB; Johansen HK; LiPuma JJ; Bell SC; Elborn JS; Flume PA; VanDevanter DR; Gilligan P;
Clin Infect Dis; 2019 Oct; 69(10):1812-1816. PubMed ID: 31056660
[TBL] [Abstract][Full Text] [Related]
11. The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis.
Ramsay KA; Sandhu H; Geake JB; Ballard E; O'Rourke P; Wainwright CE; Reid DW; Kidd TJ; Bell SC
J Cyst Fibros; 2017 Jan; 16(1):70-77. PubMed ID: 27515017
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.
Ciofu O; Tolker-Nielsen T; Jensen PØ; Wang H; Høiby N
Adv Drug Deliv Rev; 2015 May; 85():7-23. PubMed ID: 25477303
[TBL] [Abstract][Full Text] [Related]
13. Development of a PCR probe test for identifying Pseudomonas aeruginosa and Pseudomonas (Burkholderia) cepacia.
O'Callaghan EM; Tanner MS; Boulnois GJ
J Clin Pathol; 1994 Mar; 47(3):222-6. PubMed ID: 7512994
[TBL] [Abstract][Full Text] [Related]
14. Mixed morphotype susceptibility testing of Pseudomonas aeruginosa from patients with cystic fibrosis.
Dunne WM; Chusid MJ
Diagn Microbiol Infect Dis; 1987 Feb; 6(2):165-70. PubMed ID: 3102157
[TBL] [Abstract][Full Text] [Related]
15. Antibody response to Burkholderia cepacia in patients with cystic fibrosis colonized with Burkholderia cepacia and Pseudomonas aeruginosa.
Hendry J; Butler S; Elborn JS; Govan JR; Nelson J; Shale DJ; Webb AK
J Infect; 2000 Mar; 40(2):164-70. PubMed ID: 10841094
[TBL] [Abstract][Full Text] [Related]
16. Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard?
Butler SL; Doherty CJ; Hughes JE; Nelson JW; Govan JR
J Clin Microbiol; 1995 Apr; 33(4):1001-4. PubMed ID: 7540623
[TBL] [Abstract][Full Text] [Related]
17. Pseudomonas cepacia pulmonary infection in adults with cystic fibrosis: is nosocomial acquisition occurring?
Taylor RF; Dalla Costa L; Kaufmann ME; Pitt TL; Hodson ME
J Hosp Infect; 1992 Jul; 21(3):199-204. PubMed ID: 1379274
[TBL] [Abstract][Full Text] [Related]
18. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection.
Govan JR; Brown AR; Jones AM
Future Microbiol; 2007 Apr; 2(2):153-64. PubMed ID: 17661652
[TBL] [Abstract][Full Text] [Related]
19. Desulfurization of mucin by Pseudomonas aeruginosa: influence of sulfate in the lungs of cystic fibrosis patients.
Robinson CV; Elkins MR; Bialkowski KM; Thornton DJ; Kertesz MA
J Med Microbiol; 2012 Dec; 61(Pt 12):1644-1653. PubMed ID: 22918866
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in cross-infection in cystic fibrosis: Burkholderia cepacia complex, Pseudomonas aeruginosa, MRSA and Pandoraea spp.
Jones AM; Webb AK
J R Soc Med; 2003; 96 Suppl 43(Suppl 43):66-72. PubMed ID: 12906328
[No Abstract] [Full Text] [Related]
[Next] [New Search]
